CFB
TXG icon

Cullen/Frost Bankers’s 10x Genomics TXG Stock Holding History

Cullen/Frost Bankers’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-500
Closed -$71K – 1138
2020
Q4 		$71K Hold
500
– – ﹤0.01% 637
2020
Q3 		$62K Buy
+500
New +$52.5K ﹤0.01% 631

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
MCAV
Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Cullen/Frost Bankers's TXG Position: Q1 2021 in Review

Cullen/Frost Bankers sold out of 10x Genomics (TXG) in Q1 2021, closing a stake of 500 shares — an estimated $71K sold.

Cullen/Frost Bankers first reported a position in TXG in Q3 2020 and held it in 2 quarters. The position peaked at $71K in Q4 2020. 324 funds tracked by Wall St. Rank hold TXG as of Q1 2021.

  • Cullen/Frost Bankers reported no remaining 10x Genomics position as of Q1 2021 after selling out during the quarter.
  • Cullen/Frost Bankers sold 500 10x Genomics shares in Q1 2021, an estimated $71K.
  • Cullen/Frost Bankers first reported a position in 10x Genomics in Q3 2020 and held it in 2 quarters.
  • Cullen/Frost Bankers's 10x Genomics position peaked at $71K in Q4 2020.
  • 324 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2021.

Based on Cullen/Frost Bankers's 13F filing for Q1 2021, filed 5 May 2021.